VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Sangeetha Palakurthi on Strategies for Managing Resistance to Osimertinib in Patients With NSCLC

Sangeetha Palakurthi, PhD
Published: Thursday, Apr 21, 2016



Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses a study that utilized non–small cell lung cancer (NSCLC) patient-derived xenografts (PDXs) from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies.

Researchers have conducted clinical trials looking at biomarker efficacy and combination regimens to better understand patient resistance to osimertinib, Palakurthi explains. This is to help gain a greater understanding of the appropriate treatments for these patients, or to possibly extend durations of response in patients with short-term responses to osimertinib.

Therefore, a platform of NSCLC PDXs was developed in order to refine treatment strategies in these patients, Palakurthi adds.



Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses a study that utilized non–small cell lung cancer (NSCLC) patient-derived xenografts (PDXs) from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies.

Researchers have conducted clinical trials looking at biomarker efficacy and combination regimens to better understand patient resistance to osimertinib, Palakurthi explains. This is to help gain a greater understanding of the appropriate treatments for these patients, or to possibly extend durations of response in patients with short-term responses to osimertinib.

Therefore, a platform of NSCLC PDXs was developed in order to refine treatment strategies in these patients, Palakurthi adds.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x